SSA
VRTX icon

Schonfeld Strategic Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,000
Closed -$8.36M – 2592
2024
Q1 		$8.36M Buy
+20,000
New +$8.45M 0.06% 442

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Schonfeld Strategic Advisors's VRTX Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 2,901 shares worth $1.44M. The stake represents 0.01% of the portfolio and ranks #1260 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in VRTX as recently as Q1 2025.

Schonfeld Strategic Advisors first reported a position in VRTX in Q1 2016 and has held it in 31 quarters since. The position peaked at $32.9M in Q3 2024. 1,763 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Schonfeld Strategic Advisors held 2,901 shares of Vertex Pharmaceuticals worth $1.44M as of Q2 2026.
  • Vertex Pharmaceuticals was a new Schonfeld Strategic Advisors position in Q2 2026.
  • Vertex Pharmaceuticals made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #1260 holding.
  • Schonfeld Strategic Advisors first reported a position in Vertex Pharmaceuticals in Q1 2016 and has held it in 31 quarters since.
  • Schonfeld Strategic Advisors's Vertex Pharmaceuticals position peaked at $32.9M in Q3 2024.
  • 1,763 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.